Passive immunization of macaques against SIV infection
- PMID: 7966232
- DOI: 10.1111/j.1600-0684.1994.tb00118.x
Passive immunization of macaques against SIV infection
Abstract
Passive immunization with plasma from an inactivated-whole SIVmac vaccine protected monkey conferred complete or partial protection to rhesus macaques challenged intravenously 4 or 18 hours later with 10 AID50 of homologous cell-free virus. In contrast, passive immunization with inactivated plasma or purified immunoglobulin (Ig) from SIVmac infected asymptomatic monkeys failed to protect any recipients similarly challenged and may have enhanced infection and accelerated disease. Administered 24 hours post challenge, anti-SIV Ig may also have enhanced the infection.
Similar articles
-
Passive immunization of rhesus macaques against SIV infection and disease.AIDS Res Hum Retroviruses. 1995 Jul;11(7):843-54. doi: 10.1089/aid.1995.11.843. AIDS Res Hum Retroviruses. 1995. PMID: 7546912
-
Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.AIDS. 1998 Jan 1;12(1):1-10. doi: 10.1097/00002030-199801000-00001. AIDS. 1998. PMID: 9456249 Free PMC article.
-
Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells.J Med Primatol. 1994 Feb-May;23(2-3):75-82. doi: 10.1111/j.1600-0684.1994.tb00105.x. J Med Primatol. 1994. PMID: 7966237
-
SIV infection of macaques: a model for AIDS vaccine development.Dev Biol Stand. 1990;72:259-66. Dev Biol Stand. 1990. PMID: 2178124 Review.
-
Mechanisms of protection against simian immunodeficiency virus infection.Vaccine. 2002 May 6;20(15):1985-7. doi: 10.1016/s0264-410x(02)00083-x. Vaccine. 2002. PMID: 11983259 Review.
Cited by
-
Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.J Virol. 1998 Apr;72(4):3235-40. doi: 10.1128/JVI.72.4.3235-3240.1998. J Virol. 1998. PMID: 9525650 Free PMC article.
-
Simian immunodeficiency virus DNA vaccine trial in macaques.J Virol. 1996 Jun;70(6):3978-91. doi: 10.1128/JVI.70.6.3978-3991.1996. J Virol. 1996. PMID: 8648735 Free PMC article.
-
Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development.Vaccine. 2008 Jun 6;26(24):3078-85. doi: 10.1016/j.vaccine.2007.12.028. Epub 2008 Jan 10. Vaccine. 2008. PMID: 18241961 Free PMC article. Review.
-
Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.PLoS Pathog. 2019 Apr 3;15(4):e1007632. doi: 10.1371/journal.ppat.1007632. eCollection 2019 Apr. PLoS Pathog. 2019. PMID: 30943274 Free PMC article.
-
Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infection.PLoS One. 2013 Dec 4;8(12):e82528. doi: 10.1371/journal.pone.0082528. eCollection 2013. PLoS One. 2013. PMID: 24349306 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical